Amyloid imaging with AV45 (18F-florbetapir) in a cognitively normal AβPP duplication carrier

Journal of Alzheimer's Disease

Volumn 28, Issue 4, 2012, Pages 877-883

  Saint Aubert, Laure ^a,b,c   Planton, Mélanie ^a,b,d   Hannequin, Didier ^e,h   Albucher, Jean François ^a,b,d   Delisle, Marie Bernadette ^e,f   Payoux, Pierre ^a,d   Hitzel, Anne ^a,d   Viallard, Gérard ^a,b   Péran, Patrice ^a,b   Campion, Dominique ^e,h   Laquerrière, Annie ^g   Barbeau, Emmanuel J ^c   Puel, Michéle ^a,b,d   Raposo, Nicolas ^a,b,d   Chollet, François ^a,b,d   Pariente, Jérémie ^a,b,d  

^a CHU PURPAN   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Brain and Cognition Research Center in Toulouse   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e INSERM   (France)

^f CHU RANGUEIL   (France)

^g HÔPITAL CHARLES NICOLLE   (France)

^h ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer's disease; amyloid; AV45 PET; A PP duplication; cerebral amyloid angiopathy; genetics; MRI

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; FLORBETAPIR F 18;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN HEMORRHAGE; CASE REPORT; CEREBELLUM; CINGULATE GYRUS; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; GENE DUPLICATION; HUMAN; MALE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEIZURE; SOMATOSENSORY CORTEX; TEMPORAL LOBE; VASCULAR AMYLOIDOSIS;

EID: 84858020954     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111598     Document Type: Article

References (31)

1. Revesz T, Holton JL, Lashley T, Plant G, Frangione B, Rostagno A, Ghiso J (2009) Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol 118, 115-130.
2. Blom ES, Viswanathan J, Kilander L, Helisalmi S, Soininen H, Lannfelt L, Ingelsson M, Glaser A, Hiltunen M (2008) Low prevalence of APP duplications in Swedish and Finnish patients with early-onset Alzheimer's disease. Eur J Hum Genet 16, 171-175.
3. Kasuga K, Shimohata T, Nishimura A, Shiga A, Mizuguchi T, Tokunaga J, Ohno T, Miyashita A, Kuwano R, Matsumoto N, Onodera O, Nishizawa M, Ikeuchi T (2009) Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer disease. J Neurol Neurosurg Psychiatry 80, 1050-1052.
4. Biffi A, Plourde A, Shen Y, Onofrio R, Smith EE, Frosch M, Prada CM, Gusella J, Greenberg SM, Rosand J (2010) Screening for familial APP mutations in sporadic cerebral amyloid angiopathy. PLoS One 5, e13949.
5. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38, 24-26.
6. Cabrejo L, Guyant-Marechal L, Laquerriere A, Vercelletto M, De la Fourniere F, Thomas-Anterion C, Verny C, Letournel F, Pasquier F, Vital A, Checler F, Frebourg T, Campion D, Hannequin D (2006) Phenotype associated with APP duplication in five families. Brain 129, 2966-2976.
7. Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del-Favero J, Cruts M, van Duijn CM, Van Broeckhoven C (2006) APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 129, 2977-2983.
8. Guyant-Marechal I, Berger E, Laquerriere A, Rovelet-Lecrux A, Viennet G, Frebourg T, Rumbach L, Campion D, Hannequin D (2008) Intrafamilial diversity of phenotype associated with app duplication. Neurology 71, 1925-1926.
9. McNaughton D, Knight W, Guerreiro R, Ryan N, Lowe J, Poulter M, Nicholl DJ, Hardy J, Revesz T, Rossor M, Collinge J, Mead S (2012) Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. Neurobiol Aging, 33, 426.e13-21.
10. Rovelet-Lecrux A, Frebourg T, Tuominen H, Majamaa K, Campion D, Remes AM (2007) APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 78, 1158-1159.
11. Remes AM, Laru L, Tuominen H, Aalto S, Kemppainen N, Mononen H, Nagren K, Parkkola R, Rinne JO (2008) Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol 65, 540-544.
12. Knudsen KA, Rosand J, Karluk D, Greenberg SM (2001) Clinical diagnosis of cerebral amyloid angiopathy: Validation of the Boston criteria. Neurology 56, 537-539.
13. Heyman A, Fillenbaum GG, Mirra SS (1990) Consortium to Establish a Registry for Alzheimer's Disease (CERAD): clinical, neuropsychological, and neuropathological components. Aging (Milano) 2, 415-424.
14. Cordonnier C, Potter GM, Jackson CA, Doubal F, Keir S, Sudlow CL, Wardlaw JM, Al-Shahi Salman R (2009) Improving interrater agreement about brain microbleeds: development of the Brain Observer MicroBleed Scale (BOMBS). Stroke 40, 94-99.
15. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, Benedum TE, Kilbourn MR, Skovronsky D, Kung HF (2009) Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 50, 1887-1894.
16. Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, Wai YY, Chang HP, Lo CW, Yao CH, Yen TC, Kung MP (2010) Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent-a pilot study. Nucl Med Biol 37, 497-508.
17. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305, 275-283.
18. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
19. Querbes O, Aubry F, Pariente J, Lotterie JA, Demonet JF, Duret V, Puel M, Berry I, Fort JC, Celsis P (2009) Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. Brain 132, 2036-2047.
20. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27, 6174-6184.
21. Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, Nagren K, Rokka J, Haaparanta M, Kalimo H, Rinne JO (2008) PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 131, 1845-1853.
22. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319.
23. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, Dekosky ST, Fischman AJ, Greenberg SM (2007) Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 62, 229-234.
24. Ly JV, Donnan GA, Villemagne VL, Zavala JA, Ma H, O'Keefe G, Gong SJ, Gunawan RM, Saunder T, Ackerman U, Tochon-Danguy H, Churilov L, Phan TG, Rowe CC (2010) 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 74, 487-493.
25. Yates PA, Sirisriro R, Villemagne VL, Farquharson S, Masters CL, Rowe CC (2011) Cerebral microhemorrhage and brain beta-amyloid in aging and Alzheimer disease. Neurology 77, 48-54.
26. Jellinger KA (2002) Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109, 813-836.
27. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, Libri V, Leppert D, Beach TG (2007) PIB is a non-specific imaging marker of amyloid-beta (A) peptide-related cerebral amyloidosis. Brain 130, 2607.
28. Dierksen GA, Skehan ME, Khan MA, Jeng J, Nandigam RN, Becker JA, Kumar A, Neal KL, Betensky RA, Frosch MP, Rosand J, Johnson KA, Viswanathan A, Salat DH, Greenberg SM (2010) Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol 68, 545-548.
29. Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack CR Jr, Jagust W, Toga AW, Saykin AJ, Morris JC, Green RC, Weiner MW (2010) Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: Progress and plans. Alzheimers Dement 6, 239-246.
30. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355-1365.
31. Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M (2007) PET amyloid ligand [11C] PIB uptake is increased in mild cognitive impairment. Neurology 68, 1603.